Samuel Zalipsky
Nessuna posizione attualmente
Profilo
Samuel Zalipsky worked as a Principal at ALZA Corp., Enzon Pharmaceuticals, Inc., and SEQUUS Pharmaceuticals, Inc. He also served as Vice President-Technology Development at Intradigm Corp.
from 2007 to 2010.
Prior to his industry experience, he was a Professor at Rutgers State University of New Jersey.
Zalipsky holds a doctorate degree from the University of Minnesota and undergraduate and graduate degrees from The Hebrew University of Jerusalem.
Precedenti posizioni note di Samuel Zalipsky
| Società | Posizione | Fine |
|---|---|---|
Intradigm Corp.
 Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 |
| Rutgers State University of New Jersey | Corporate Officer/Principal | - |
| ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Corporate Officer/Principal | - |
| ALZA CORPORATION | Corporate Officer/Principal | - |
Formazione di Samuel Zalipsky
| University of Minnesota | Doctorate Degree |
| The Hebrew University of Jerusalem | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Intradigm Corp.
Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
- Borsa valori
- Insiders
- Samuel Zalipsky
